‘Teva’: Positive Results In Phase III Trial For Rhinitis Nasal Spray

Teva Pharmaceutical Industries reported positive results from Phase III clinical studies for its QNASL nasal spray. The spray is designed to treat seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The trials tested the efficacy and safety of the spray, as well as the impact on quality of life. The results were reported at the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) meeting in Orlando, Florida. View and share